Advertisement

International Journal of Hematology

, Volume 100, Issue 2, pp 119–124 | Cite as

Telephone versus office-based management of warfarin: impact on international normalized ratios and outcomes

  • Laura G. Stoudenmire
  • Christina E. DeRemer
  • Hazem ElewaEmail author
Original Article

Abstract

Studies have concluded that telephone-based management of warfarin is an effective alternative to in-office management. High rates of patient and physician satisfaction have been reported with telephone-based monitoring. Proposed benefits of telephone-based monitoring include time- and cost savings for patients and healthcare providers alike as well as increased access to care for those patients who have difficulty making in-office appointments. This study aimed to evaluate the impact of telephone versus office-based management of warfarin on extreme INR values. A retrospective cohort study was conducted to assess outcomes of patients receiving warfarin managed either by telephone or in-office appointments. The primary endpoint of the study was the frequency of extreme INR values, defined as an INR ≤1.5 or ≥4.5. A total of 110 patients were evaluated; subjects were distributed 2:1 between the in-office and telephone groups. Baseline characteristics were similar between groups. Subjects followed via telephone had a twofold increase in the incidence of extreme INR values compared to the patients followed in-office (15.18 vs. 7.98 %; p < 0.0001). Overall TTR was similar between groups (85.39 vs. 80.38 %, p = 0.1171). There was no difference between the two groups in the incidence of major bleeding events (2.67 vs. 0 %, p = 1.00), thromboembolic events (8 vs. 0 %, p = 0.1740), or hospitalizations related to anticoagulation therapy (6.67 vs. 0 %, p = 0.1758). Patients monitored via telephone had a higher incidence of extreme INR values than patients followed in-office, which may lead to an increased incidence of adverse outcomes in the long-term. Well-designed, prospective studies are needed to confirm such findings.

Keywords

Anticoagulation clinic Monitoring Warfarin Telephone Pharmacist managed 

Notes

Conflict of interest

The authors have no conflict of interest to report.

References

  1. 1.
    Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf. 2006;5(3):433–51.PubMedCrossRefGoogle Scholar
  2. 2.
    Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol. 2006;62(5):509–11.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Waterman AD, Milligan PE, Banet GA, Gatchel SK, Gage BF. Establishing and running an effective telephone-based anticoagulation service. J Vasc Nurs. 2001;19(4):126–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Kimmel SE. Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother. 2008;9(5):677–86.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):7S–47S.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patients outcomes, and health care costs. Arch Intern Med. 1998;158:1641–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Garabedian-Ruffalo SM, Gray DR, Sax MJ, Ruffalo RL. Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. Am J Hosp Pharm. 1985;42(2):304–8.PubMedGoogle Scholar
  8. 8.
    Gray DR, Garabedian-Ruffalo SM, Chretien SD. Cost-justification of a clinical pharmacist-managed anticoagulation clinic. Drug Intell Clin Pharm. 1985;19:575–80.PubMedGoogle Scholar
  9. 9.
    Wittkowsky A, Nutescu EA, Blackburn J, Mullins J, Hardman J, Mitchell J, et al. Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic settings. Chest. 2006;130(5):1385–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Goldberg Y, Meytes D, Shabtai E, Shinron O, Shainberg B, Seligsohn U, et al. Monitoring oral anticoagulant therapy by telephone communication. Blood Coagul Fibrinolysis. 2005;16:227–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med. 2011;155(10):653–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Martin LR, Williams SL, Haskard KB, DiMatteo MR. The challenge of patient adherence. Ther Clin Risk Manag. 2005;1(3):189–99.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028–35.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2014

Authors and Affiliations

  • Laura G. Stoudenmire
    • 1
  • Christina E. DeRemer
    • 2
  • Hazem Elewa
    • 3
    Email author
  1. 1.Department of PharmacySaint Thomas Rutherford HospitalMurfreesboroUSA
  2. 2.Department of PharmacyGeorgia Regents Health SystemAugustaUSA
  3. 3.Clinical Pharmacy and Practice Section, College of PharmacyQatar UniversityDohaQatar

Personalised recommendations